House investigation finds FDA, drug firm Biogen ignored internal concerns for Alzheimer’s drug
(WASHINGTON) -- A congressional investigation into the Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug with inconsistent data.Aduhelm is notable for being the first drug in recent years...